Insulet Co. (NASDAQ:PODD) Shares Acquired by American Capital Management Inc.

American Capital Management Inc. lifted its holdings in shares of Insulet Co. (NASDAQ:PODD) by 27.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,800 shares of the medical instruments supplier’s stock after acquiring an additional 3,197 shares during the quarter. American Capital Management Inc.’s holdings in Insulet were worth $3,445,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Marshall Wace LLP acquired a new position in shares of Insulet during the second quarter worth about $99,978,000. Baillie Gifford & Co. raised its holdings in shares of Insulet by 30.8% during the 2nd quarter. Baillie Gifford & Co. now owns 1,886,062 shares of the medical instruments supplier’s stock valued at $380,607,000 after buying an additional 443,783 shares during the period. Mizuho Securities USA LLC lifted its position in Insulet by 5,928.1% during the 3rd quarter. Mizuho Securities USA LLC now owns 325,821 shares of the medical instruments supplier’s stock worth $75,835,000 after acquiring an additional 320,416 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Insulet by 43.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock worth $148,091,000 after acquiring an additional 193,839 shares during the period. Finally, Westfield Capital Management Co. LP grew its position in Insulet by 27.6% in the third quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock valued at $175,697,000 after acquiring an additional 163,388 shares in the last quarter.

Insulet Stock Down 0.1 %

PODD opened at $266.78 on Friday. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $279.40. The stock’s 50 day moving average price is $244.40 and its 200 day moving average price is $213.85. The stock has a market cap of $18.71 billion, a P/E ratio of 45.68, a P/E/G ratio of 4.08 and a beta of 1.22.

Analysts Set New Price Targets

A number of research analysts have recently commented on PODD shares. Piper Sandler boosted their target price on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 17th. Citigroup upped their price objective on shares of Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a research report on Tuesday, October 1st. Morgan Stanley raised their target price on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Sanford C. Bernstein initiated coverage on Insulet in a research note on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price target on the stock. Finally, Canaccord Genuity Group raised their price objective on Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Three analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.27.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.